Regulatory circuits of T cell function in cancer (Q38928127)

7 September 2017

1 reference

title

Regulatory circuits of T cell function in cancer (English)

1 reference

7 September 2017

1 reference

1 reference

7 September 2017

Daniel E Speiser

1 reference

7 September 2017

Ping-Chih Ho

series ordinal

1 reference

7 September 2017

publication date

16 August 2016

1 reference

Nature Reviews Immunology

7 September 2017

published in

1 reference

7 September 2017

1 reference

7 September 2017

1 reference

7 September 2017

page(s)

599-611

1 reference

Transcriptional control of effector and memory CD8+ T cell differentiation

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Balancing Immune Protection and Immune Pathology by CD8(+) T-Cell Responses to Influenza Infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Microenvironmental regulation of tumor progression and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Immunological hallmarks of stromal cells in the tumour microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Regulatory T cells in cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Myeloid-derived suppressor cells as regulators of the immune system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Activated CD69+ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Functional polarization of tumour-associated macrophages by tumour-derived lactic acid.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Accessories to the crime: functions of cells recruited to the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Agonistic CD40 antibodies and cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

31 March 2020

Fibroblasts in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Fibroblasts as architects of cancer pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

31 March 2020

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Metabolism of stromal and immune cells in health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Emerging roles of lymphatic endothelium in regulating adaptive immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Metabolic regulation of T lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Inhibitory effect of tumor cell-derived lactic acid on human T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Bicarbonate increases tumor pH and inhibits spontaneous metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Acidity generated by the tumor microenvironment drives local invasion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Mechanisms of enhanced macrophage-mediated prostaglandin E2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE₂ catabolism in myeloid cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Coordinated regulation of myeloid cells by tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Acquired resistance to immunotherapy and future challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Molecular and genetic properties of tumors associated with local immune cytolytic activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Missing self recognition and self tolerance of natural killer (NK) cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Adaptations of Natural Killer Cells to Self-MHC Class I.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

The blockade of immune checkpoints in cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Innate immune recognition of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

The three main stumbling blocks for anticancer T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Clinical blockade of PD1 and LAG3--potential mechanisms of action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Restoring function in exhausted CD8 T cells during chronic viral infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Viral immune evasion due to persistence of activated T cells without effector function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Molecular and cellular insights into T cell exhaustion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Contribution of TCR signaling strength to CD8+ T cell peripheral tolerance mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

The TGF-β-Smad3 pathway inhibits CD28-dependent cell growth and proliferation of CD4 T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Inhibitory Receptors Beyond T Cell Exhaustion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Transcriptional regulation of T lymphocyte development and function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

The transcription factor NFAT promotes exhaustion of activated CD8⁺ T cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Nr4a receptors are essential for thymic regulatory T cell development and immune homeostasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Nuclear receptor Nr4a1 modulates both regulatory T-cell (Treg) differentiation and clonal deletion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Nuclear receptor NR4A2 orchestrates Th17 cell-mediated autoimmune inflammation via IL-21 signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

IL-27 and IL-12 oppose pro-inflammatory IL-23 in CD4+ T cells by inducing Blimp1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Expression of IL-27 by tumor cells in invasive cutaneous and metastatic melanomas [corrected]..

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Potent antitumor activity of interleukin-27.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

STAT3 Signaling Is Required for Optimal Regression of Large Established Tumors in Mice Treated with Anti-OX40 and TGFβ Receptor Blockade.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Pembrolizumab versus Ipilimumab in Advanced Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Pembrolizumab for the treatment of non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

T cell exclusion, immune privilege, and the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Adoptive cellular therapy: a race to the finish line.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

A human memory T cell subset with stem cell-like properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Activated STAT5 promotes long-lived cytotoxic CD8+ T cells that induce regression of autochthonous melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Active STAT5 regulates T-bet and eomesodermin expression in CD8 T cells and imprints a T-bet-dependent Tc1 program with repressed IL-6/TGF-β1 signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Inducible in vivo genome editing with CRISPR-Cas9

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

SnapShot: T Cell Exhaustion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Combination cancer immunotherapies tailored to the tumour microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

The immune contexture in human tumours: impact on clinical outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

IL-7-Induced Glycerol Transport and TAG Synthesis Promotes Memory CD8+ T Cell Longevity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

T cell metabolic fitness in antitumor immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Emerging concepts of T cell metabolism as a target of immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Memory T cell subsets, migration patterns, and tissue residence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

The emerging role of resident memory T cells in protective immunity and inflammatory disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Hallmarks of Tissue-Resident Lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Cancer immunotherapy drives implementation science in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2016.80

Prognostic and predictive markers for the new immunotherapies.

31 March 2020

1 reference

12 December 2020

Leukocyte recruitment at sites of tumor: dissonant orchestration

1 reference

12 December 2020

Genomic Classification of Cutaneous Melanoma

1 reference

12 December 2020

Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRI.2016.80

1 reference

7 September 2017

1 reference